Overview

Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment

Status:
Completed

Trial end date:
2021-04-08

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of AKST4290 in subjects with Parkinson's Disease who are currently on stable dopaminergic treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Alkahest, Inc.